There may be two distinct subtypes of multiple sclerosis, according to a new study led by scientists at University College ...

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

The chronic progressive multiple sclerosis market size is anticipated to grow during the forecast period (2025–2034). According to DelveInsight's analysis, this growth is expected to be driven by the ...

Inspiratory muscle training (IMT) provides significant benefits to patients with advanced multiple sclerosis (MS), and those benefits are retained 8 weeks after cessation of training, according to a ...

A new multiple sclerosis (MS) drug, siponimod (Mayzent), significantly improves cognition for patients with advanced disease, new research shows. Results of a randomized placebo controlled trial ...

MINNEAPOLIS - Finding treatments for advanced multiple sclerosis (MS) has been difficult. But new research may help neurologists identify which drugs are best for people with the advanced form of MS ...

People with secondary progressive multiple sclerosis who take the drug siponimod for two years show an improvement in thinking skills, a new study has found. Siponimod, sold as Mayzent, was approved ...

Four in 10 people with advanced multiple sclerosis, or MS, are emotionally abused by someone responsible for caring for them, reports a study led by the University of California, Riverside. Further, ...

The market size for chronic progressive multiple sclerosis in the leading markets is expected to grow significantly by 2034. The United States accounted for the highest chronic progressive multiple ...